These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22745587)

  • 1. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
    Haupenthal J; Bihrer V; Korkusuz H; Kollmar O; Schmithals C; Kriener S; Engels K; Pleli T; Benz A; Canamero M; Longerich T; Kronenberger B; Richter S; Waidmann O; Vogl TJ; Zeuzem S; Piiper A
    Neoplasia; 2012 May; 14(5):410-9. PubMed ID: 22745587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
    Tian L; Yao K; Liu K; Han B; Dong H; Zhao W; Jiang W; Qiu F; Qu L; Wu Z; Zhou B; Zhong M; Zhao J; Qiu X; Zhong L; Guo X; Shi T; Hong X; Lu S
    Oncogene; 2020 Apr; 39(15):3145-3162. PubMed ID: 32060423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
    Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
    Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
    Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
    Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
    Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
    J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
    Stewart HJ; Kishikova L; Powell FL; Wheatley SP; Chevassut TJ
    Exp Hematol; 2011 Mar; 39(3):330-8. PubMed ID: 21184800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
    Diab A; Foca A; Fusil F; Lahlali T; Jalaguier P; Amirache F; N'Guyen L; Isorce N; Cosset FL; Zoulim F; Andrisani O; Durantel D
    Hepatology; 2017 Dec; 66(6):1750-1765. PubMed ID: 28445592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
    Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
    Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
    Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
    Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
    Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
    Deng Z; Chen G; Liu S; Li Y; Zhong J; Zhang B; Li L; Huang H; Wang Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Nov; 206():112697. PubMed ID: 32814244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
    Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.
    Zhou J; Gao Q; Chen G; Huang X; Lu Y; Li K; Xie D; Zhuang L; Deng J; Ma D
    Clin Cancer Res; 2005 Dec; 11(23):8431-40. PubMed ID: 16322306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.